Member Info for Laura2022

Amd this time there will be no overhang to stop the re -rate

Recent Trading update :

"Tekmar highlighted the increasing strength of its visible pipeline, with in excess of £50m of projects scheduled for award in the second half of the calendar year to December 2025

Thanks Smkrs

On the 4th Sept

Shroeders confirmed the amount of :

13,792,873.00

Between 4th and 12th Sept there has been at least that in round/grey trades sells

Should get the TR1 next week

I've asked PR to put the presentation on the website

This is PYC specialty

Key TakeawaysModel-informed precision dosing (MIPD) enhances demand forecasting, reducing overproduction and costly inventory write-offs, especially for high-cost biologics and cell therapies.MIPD reduces drug waste in high-stakes areas like oncology and transplantation, addressing financial waste and clinical risk, improving drug utilization efficiency.Precision dosing tools support market access by demonstrating value per dose, aiding reimbursement and pricing negotiations, and aligning with health technology assessments.MIPD accelerates the adoption of complex therapies by simplifying dosing decisions, reducing prescriber friction, and improving clinician confidence, enhancing early revenue opportunities.

Morning Trench

Interesting when you then look back to July 10th update

Expansion of collaboration

Physiomics and DoseMe have recently signed non-binding Heads of Terms with the intention of expanding their partnership beyond the Company's current personalised dosing software. This agreement defines terms across four areas of collaboration:

· development and commercialisation of novel dosing software tools originating from Physiomics;

· development and commercialisation of novel dosing software tools originating from DoseMe or its clients;

· provision of consultancy services by the Company to DoseMe; and

· co-development of clinical trial dosing software in support of biopharmaceutical clients.

The two parties are actively working to identify potential projects falling under these umbrella categories and further announcements on this will be made when appropriate.

Allowing about £2000 to be bought...that's it

Going very well from sub £2

The buy backs now taking real affect

Hi KingH

Just to show the hypocrisy with the person I filtered

Had 50mln

Already 27mln volume today (+ whatever after hours delayed )

Opportunity?

Peer comparisons

PYC losses £419k and made £834k revs- CEO salary £72k

FAB losses  £1.7mln to make £1.96mln revs- CEO £169k (30% increase)

APTA £35mln cap and £1.2mln full year revs( = x 30 annual rev)

FAB £17 mln and £1.96mln full year ( x 9)

PYC £1.4mln and £0.85mln full year ( x less than 2 )

IMM £50mln cap (pre revenue)

I deduce from your comments thread that Trout is CONTINUING to spend 95% of his time here

Really is illogical

Above ask

Yes both

Nt to buy now for 2hrs

Can anyone buy at 5 75p?

Looking ahead to the rest of the financial year, the addressable order volume and value across our markets is significant with a visible pipeline of over £400m, of which in excess of £50m of projects are scheduled for award in the second half of this calendar year. We have a number of significant tender opportunities across all revenue lines as well as a material volume of "in and out" work.

Managed to get 18,000 Fill or Kill 5.5p

Davey

Good purchases and now NT at 5.5p

Results will confirm a 40% jump in revenues and double digit % improvement on all key metrics

1 new clients

2 reduced losses

3 pipeline

4 forward order book

£1.4mln cap and valued less than x 2 earnings versus peers who are valued x 10-30

7th August : follow on contract with leader in A.i medicine. Phase 1 trial , £38k over 2 mths

16th July - new contract with partner Numab

14th July - Trading statement

ahead of expectations for FY25. When compared to the year ended 30 June 2024 (FY24), these unaudited numbers would represent an increase in Total Income of approximately 46%

10th July : integration of PYC platform into global personalosed medical provoder DoseMeRx

1st July - new contract and a Master Service Agreement for deeper relationship

16th June x 2 biostatistics contracts (first ones from new division)

29th May RNSPhysiomics Awarded Contract Extension

9th May RNSContract Award with New UK Client

17th Apr Physiomics Awarded New Contract

16th Apr RNS-R Publication of Peer Reviewed Article

15th Apr new contract

17th Mar RNS Contract Award with new client

A free hold asset being held for sale at £2.8mln

The current market value looks severely undervalued

"nterim results announced on 26 June 2025, Tekmar highlighted the increasing strength of its visible pipeline, with in excess of £50m of projects scheduled for award in the second half of the calendar year to December 2025".

They also have a total visibility over £400mln worth of business